CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0638 (clinicaltrials.gov NCT No: NCT00543504)
Title:A PHASE 1 STUDY OF BEVACIZUMAB IN COMBINATION WITH 1) SUNITINIB, 2) SORAFENIB, 3) ERLOTINIB AND CETUXIMAB, 4) TRASTUZUMAB AND LAPATINIB
Principal Investigator:Gerald Falchook
Treatment Agent:Bevacizumab; Cetuximab; Erlotinib; Lapatinib; Sorafenib; Sunitinib Malate; Trastuzumab
Study Status:Closed
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Bevacizumab
Cetuximab
Erlotinib
Lapatinib
Sorafenib
Sunitinib Malate
Trastuzumab
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients are seen and evaluated in the phase I clinic weekly during cycle 1,
and at the end of each cycle thereafter. Other visits include the IV
treatments specified by the study and optional research correlative studies
(blood draws, DCE-MRI).
Home Care:Patient will be given oral medication (sorafenib, sunitinib, erlotinib,
lapatinib) per treatment protocol to take at home.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gerald Falchook
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults